The Irish Pharmaceutical Healthcare Association (IPHA) has welcomed a call from a group of organisations representing patients, healthcare professionals and the health care industry to the EU and UK to prioritise patients in the Brexit negotiations.
The Irish Pharmaceutical Healthcare Association (IPHA), which represents 47-research based pharmaceutical companies in Ireland, has warmly welcomed the latest National Cancer Registry Annual Report.
BioPharmaChemIreland (BPCI)- the Ibec group that represents the sector, alongside the Irish Pharmaceutical Healthcare Association (IPHA) and the National Institute for Bioprocessing Research and Training (NIBRT), have joined forces to promote the biopharmaceutical industry in Ireland as a global powerhouse, generating revenue of €66 billion per annum.
The Irish Pharmaceutical Healthcare Association has welcomed the reduction of prescription charges and the lowering of the Drugs Payment Scheme threshold in today.
Responding to the publication of a study in the British Medical Journal (BMJ) concerning the benefits on overall survival and quality of life of approved cancer medicines, the IPHA, which represents 44 research based pharmaceutical companies in Ireland, many of whom are providing key oncology medicines, has stated that new therapies have contributed to significant declines in cancer death rates around the world since its peak in 1991.
IPHA has launched a briefing document which sets out how Irish patients are being denied access to new medicines that are readily available in other Western European countries. s.
In a submission made to the National Biosimilar Medicines Policy consultation process, the Irish Pharmaceutical Healthcare Association (IPHA) highlighted the importance of adopting a patient-centric policy on prescribing biologic and biosimilar medicines.